174 related articles for article (PubMed ID: 35528020)
21. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
23. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
24. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
[TBL] [Abstract][Full Text] [Related]
25. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
26. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
27. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K; Makino Y; Pereira T; Poellinger L
EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
[TBL] [Abstract][Full Text] [Related]
29. RWD Domain as an E2 (Ubc9)-Interaction Module.
Alontaga AY; Ambaye ND; Li YJ; Vega R; Chen CH; Bzymek KP; Williams JC; Hu W; Chen Y
J Biol Chem; 2015 Jul; 290(27):16550-9. PubMed ID: 25918163
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
31. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
Palayoor ST; Burgos MA; Shoaibi A; Tofilon PJ; Coleman CN
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4158-64. PubMed ID: 15217953
[TBL] [Abstract][Full Text] [Related]
32. Differential gene expression in models of pituitary prolactin-producing tumoral cells.
Giacomini D; Haedo M; Gerez J; Druker J; Páez-Pereda M; Labeur M; Stalla GK; Arzt E
Horm Res; 2009 Apr; 71 Suppl 2():88-94. PubMed ID: 19407504
[TBL] [Abstract][Full Text] [Related]
33. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
34. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
35. RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha.
van Hagen M; Overmeer RM; Abolvardi SS; Vertegaal AC
Nucleic Acids Res; 2010 Apr; 38(6):1922-31. PubMed ID: 20026589
[TBL] [Abstract][Full Text] [Related]
36. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.
Hughson MD; He Z; Liu S; Coleman J; Shingleton WB
Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
38. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
39. Molecular targets from VHL studies into the oxygen-sensing pathway.
Maynard MA; Ohh M
Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382
[TBL] [Abstract][Full Text] [Related]
40. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]